摘要
目的:观察吉非替尼与多西他赛二线治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效及毒副作用。方法:78例一线化疗失败晚期NSCLC患者,随机分为吉非替尼组和多西他赛组,吉非替尼组:英国阿斯利康公司生产吉非替尼(易瑞沙)250mg,每天一次口服,维持治疗直至病情进展或出现不能耐受的不良反应。多西他赛组:江苏恒瑞公司产多西他赛(艾素)75mg/m2,静滴1h,第1天,每21天重复,至少接受2个疗程。结果:78例NSCLC均可评价疗效,吉非替尼组40例CR+PR10例,有效率25.0%,中位生存时间为7.2个月,多西他赛组38例,CR+PR7例,有效率18.4%,中位生存时间为6.8个月,两组有效率相当(P=0.785)。在病理类型亚组分析,吉非替尼组中腺癌亚组的治疗有效率及中位生存期有明显优势。两组的主要不良反应不同。吉非替尼组皮疹发生率分别为80.0%,明显高于多西他赛组(P<0.01),多西他赛组白细胞减少血小板减少发生率明显高于吉非替尼组(P=0.000)。吉非替尼组耐受性更好,但治疗费用高于多西他赛组。结论:作为二线药物治疗晚期非小细胞肺癌,吉非替尼与多西他赛相比,疗效相近,不良反应轻,耐受性好,生存质量改善率更高,特别值得推荐于非小细胞肺癌EGFR突变者优势人群。
Objective：To observe the efficacys and side effect of Gefitinib（Iressa） and Docetaxel（aisu） as the second-line treatment for advanced non-small cell lung cancer（NSCLC） patients.Methods：A total of 78 patients with advanced non-small cell lung cancer who had failed to previous first-line chemotherapy were randomly divided into two groups：gefitinib group and docetaxel group.In the gefitinib group,UK Astra Zeneca Gefitinib（Iressa） 250 mg orally once daily,maintenance therapy until disease progression can not tolerate the side effects.In the docetaxel group,Jiangsu Hengrui company producing docetaxel（docetaxel） 75 mg/m2,1 hour intravenous infusion,the first day,the regimen was repeated every 21 days for at least 2 consecutive cycles.Results：78 cases of NSCLC can be evaluated,Gefitinib group of 40 patients CR＋PR 10 case,the response rate was 25.0%,the median survival time was 7.2 months.Docetaxel group of 38 patients CR＋PR 7 case,the response rate was 18.4%,the median survival time was 6.8 months.Two groups had the same efficiency（P=0.785）.In the subgroup analysis of histological type,Gefitinib group adenocarcinoma subgroup of treatment efficiency and a significant median survival advantage.The main adverse reactions of different groups.The incidences of rash were 80.0% in the gefitinib group,significantly higher than the docetaxel group（P0.01）.Docetaxel group leukopenia thrombocytopenia were significantly higher than the gefitinib group（P=0.000）.Gefitinib group had a better tolerability.However,the cost of treatment was higher than docetaxel group.Conclusion：As second-line treatment of advanced non-small cell lung cancer,Gefitinib compared with docetaxel,has similar efficacy,adverse reactions,well tolerated,higher survival rate of quality improvement,especially recommended for EGFR mutations in non-small cell lung cancer who benefits the crowd.
出处
《中外医学研究》
2012年第14期7-9,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
吉非替尼
多西他赛
非小细胞肺癌
化疗
Gefitinib
Docetaxel
Non-small cell lung cancer
Chemotherapy
